Pedro Isaacsson Velho
Overview
Explore the profile of Pedro Isaacsson Velho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
738
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gillessen S, Tombal B, Turco F, Choudhury A, Rodriguez-Vida A, Gallardo E, et al.
Eur Urol
. 2025 Jan;
87(3):285-288.
PMID: 39827019
Bone health is central to the management of patients with metastatic castration-resistant prostate cancer (mCRPC). International guidelines recommend giving a bone-protecting agent (BPA) to patients with mCRPC and bone metastases....
2.
Dos Reis R, Aguilar-Ponce J, Cayol F, Jansen A, K R, Merino T, et al.
Cancer Control
. 2024 Oct;
31:10732748241280446.
PMID: 39387315
In Latin America, prostate cancer is the third most common cancer overall and the most common in men, with the highest mortality rate of all cancers. In 2022, there were...
3.
Velho P, Bastos D, Saintana P, Rigatti B, da Costa E, Muniz D, et al.
Clin Cancer Res
. 2024 Sep;
30(23):5342-5352.
PMID: 39330991
Purpose: Despite the success of immune checkpoint inhibitors (ICI) across various cancers, their efficacy in metastatic castration-resistant prostate cancer (mCRPC) is modest, except for a subset of patients who experience...
4.
Soares A, Marques Monteiro F, da Trindade K, Silva A, Cardoso A, Sasse A, et al.
J Cancer Res Clin Oncol
. 2024 Apr;
150(4):183.
PMID: 38594593
Purpose: Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however,...
5.
Basso J, de Lima J, Bessel M, Tobar Leitao S, Machado Baptista T, Roithmann S, et al.
BMC Urol
. 2023 Dec;
23(1):208.
PMID: 38082337
Background: Prostate cancer exhibits a very diverse behaviour, with some patients dying from the disease and others never needing treatment. Active surveillance (AS) consists of periodic PSA assessment (prostate-specific antigen),...
6.
Nabavi N, Mahdavi S, Afshar Ardalan M, Chamanara M, Mosaed R, Lara A, et al.
Biomedicines
. 2023 Jul;
11(7).
PMID: 37509723
Androgen deprivation therapy (ADT) remains the cornerstone of advanced prostate cancer treatment. However, the progression towards castration-resistant prostate cancer is inevitable, as the cancer cells reactivate androgen receptor signaling and...
7.
Talukder R, Makrakis D, Diamantopoulos L, Carril-Ajuria L, Castellano D, de Kouchkovsky I, et al.
Clin Genitourin Cancer
. 2022 Jan;
20(2):165-175.
PMID: 35078711
Background: Immune checkpoint inhibitors (ICI) improve overall survival (OS) in patients with locally advanced, unresectable, or metastatic urothelial carcinoma (aUC), but response rates can be modest. We compared outcomes between...
8.
Gongora A, Marshall C, Velho P, Lopes C, Marin J, Camargo A, et al.
Clin Genitourin Cancer
. 2022 Jan;
20(2):183-188.
PMID: 35027313
No abstract available.
9.
Nakazawa M, Fang M, Marshall C, Lotan T, Velho P, Antonarakis E
Prostate
. 2021 Nov;
82(2):260-268.
PMID: 34783071
Background: Inactivating missense mutations in the SPOP gene, encoding speckle-type poxvirus and zinc-finger protein, are one of the most common genetic alterations in prostate cancer. Methods: We retrospectively identified 72...
10.
Velho P, Bastos D, Antonarakis E
Clin Adv Hematol Oncol
. 2021 May;
19(4):228-240.
PMID: 33989272
The androgen signaling axis has been the main therapeutic target in the management of advanced prostate cancer for several decades. Over the past years, significant advances have been made in...